![Acadia Pharmaceuticals](https://www.adcreviews.com/wp-content/uploads/2022/07/Acadia-Pharmaceuticals-300x173.jpg)
Acadia Submits New Drug Application for Rett syndrome
SAN DIEGO–(BUSINESS WIRE)–Jul. 18, 2022– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the company has submitted a New Drug Application (NDA) to the U.S.
SAN DIEGO–(BUSINESS WIRE)–Jul. 18, 2022– Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the company has submitted a New Drug Application (NDA) to the U.S.